Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients

Kidney International

Volumn 68, Issue 6, 2005, Pages 2814-2822

  Schaller, Georg ^b   Scheiber Mojdehkar, Barbara ^b   Wolzt, Michael ^b   Puttinger, Heidi ^b   Mittermayer, Friedrich ^b   Hörl, Walter H ^b   Födinger, Manuela ^b   Sunder Plassmann, Gere ^b   Vychytil, Andreas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Intravenous iron; Peritoneal dialysis; Vascular function

Indexed keywords

FERRIC HYDROXIDE SUCROSE; GLYCERYL TRINITRATE;

ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOREARM BLOOD FLOW; HEMODIALYSIS PATIENT; HUMAN; IRON BLOOD LEVEL; MALE; PERITONEAL DIALYSIS; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANEMIA; FEMALE; FERRIC COMPOUNDS; FOREARM; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; VASODILATION;

EID: 32844456417     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00754.x     Document Type: Article

References (46)

1. SUNDER-PLASSMANN G, HÖRL WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
2. AHSAN N: Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: A single center comparative study. J Am Soc Nephrol 9:664-668, 1998
3. VYCHYTIL A, HAAG-WEBER M: Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int 55(Suppl 69):S71-78, 1999
4. DITTRICH E, SCHILLINGER M, SUNDER-PLASSMANN G, et al: Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients. Perit Dial Int 22:60-66, 2002
5. KOOISTRA MP, MARX JJ: The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial Transplant 13:2578-2582, 1998
6. CHANDLER G, HARCHOWAL J, MACDOUGALL IC: Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 38:988-991, 2001
7. DEICHER R, ZIAI F, COHEN G, et al: High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 64:728-736, 2003
8. PATRUTA SI, EDLINGER R, SUNDER-PLASSMANN G, HÖRL WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9:655-663, 1998
9. SUNDER-PLASSMANN G, PATRUTA SI, HÖRL WH: Pathobiology of the role of iron in infection. Am J Kidney Dis 34(Suppl 2):S25-29, 1999
10. SMITH C, MITCHINSON MJ, ARUOMA OI, HALLIWELL B: Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J 286:901-905, 1992
11. COOPER CE: Nitric oxide and iron proteins. Biochim Biophys Acta 1411:290-309, 1999
12. ROOB JM, KHOSCHSORUR G, TIRAN A, et al: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539-549, 2000
13. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med 340:115-126, 1999
14. HOKANSON DE, SUMNER DS, STRANDNESS DE, JR.: An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans Biomed Eng 22:25-29, 1975
15. PLEINER J, HEERE-RESS E, LANGENBERGER H, et al: Adrenoceptor hyporeactivity is responsible for Escherichia coli endotoxin-induced acute vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 22:95-100, 2002
16. BENJAMIN N, CALVER A, COLLIER J, et al: Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 25:918-923, 1995
17. BREUER W, RONSON A, SLOTKI IN, et al: The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 95:2975-2982, 2000
18. ESPOSITO BP, BREUER W, SIRANKAPRACHA P, et al: Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood 102:2670-2677, 2003
19. HÖRL WH, JACOBS C, MACDOUGALL IC, et al: European best practice guidelines 14-16: Inadequate response to epoetin. Nephrol Dial Transplant 15(Suppl 4):43-50, 2000
20. KIECHL S, WILLEIT J, EGGER G, et al: Body iron stores and the risk of carotid atherosclerosis: Prospective results from the Bruneck study. Circulation 96:3300-3307, 1997
21. TUOMAINEN TP, PUNNONEN K, NYYSSONEN K, SALONEN JT: Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 97:1461-1466, 1998
22. TUOMAINEN TP, KONTULA K, NYYSSONEN K, et al: Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: A prospective cohort study in men in eastern Finland. Circulation 100:1274-1279, 1999
23. SALONEN JT, TUOMAINEN TP, SALONEN R, et al: Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol 148:445-451, 1998
24. CHEUNG YF, CHAN GC, HA SY: Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation 106:2561-2566, 2002
25. GAENZER H, MARSCHANG P, STURM W, et al: Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol 40:2189-2194, 2002
26. DUFFY SJ, BIEGELSEN ES, HOLBROOK M, et al: Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 103:2799-2804, 2001
27. RODRIGUEZ-CRESPO I, NISHIDA CR, KNUDSEN GM, DE MONTELLANO PR: Mutation of the five conserved histidines in the endothelial nitric-oxide synthase hemoprotein domain. No evidence for a non-heme metal requirement for catalysis. J Biol Chem 274:21617-21624, 1999
28. TAMPO Y, KOTAMRAJU S, CHITAMBAR CR, et al: Oxidative stress-induced iron signaling is responsible for peroxide-dependent oxidation of dichlorodihydrofluorescein in endothelial cells: Role of transferrin receptor-dependent iron uptake in apoptosis. Circ Res 92:56-63, 2003
29. ROOYAKKERS TM, STROES ES, KOOISTRA MP, et al: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32(Suppl 1):9-16, 2002
30. KLETZMAYR J, HÖRL WH: Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 17(Suppl 2):25-29, 2002
31. ROSELAAR SE, NAZHAT NB, WINYARD PG, et al: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 48:199-206, 1995
32. MORENA M, CRISTOL JP, CANAUD B: Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purif 18:191-199, 2000
33. HIMMELFARB J, HAKIM RM: Oxidative stress in uremia. Curr Opin Nephrol Hypertens 12:593-598, 2003
34. LIM PS, WEI YH, Yu YL, KHO B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14:2680-2687, 1999
35. KOOISTRA MP, KERSTING S, GOSRIWATANA I, et al: Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Ear J Clin Invest 32(Suppl 1):36-41, 2002
36. AGARWAL R, VASAVADA N, SACHS NG, CHASE S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279-2289, 2004
37. SCHEIBER-MOJDEHKAR B, LUTZKY B, SCHAUFLER R, et al: Nontransferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: No correlation to peroxide generation. J Am Soc Nephrol 15:1648-1655, 2004
38. HERRERA J, NAVA M, ROMERO F, RODRIGUEZ-ITURBE B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 37:750-757, 2001
39. DRÜEKE T, WITKO-SARSAT V, MASSY Z, et al: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002
40. GOLBERG L: Pharmacology of parenteral iron preparations, in Iron in Clinical Medicine, edited by Wallerstein RO, Mettier SR, Berkeley, University of California Press, 1958, pp 74-92
41. VAN GULDENER C, JANSSEN MJ, LAMBERT J, et al: Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 13:1782-1786, 1998
42. VAN GULDENER C, LAMBERT J, JANSSEN MJ, et al: Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 12(Suppl 2):14-18, 1997
43. PLEINER J, MITTERMAYER F, SCHALLER G, et al: High doses of vitamin C reverse Escherichia coli endotoxin-induced hyporeactivity to acetylcholine in the human forearm. Circulation 106:1460-1464, 2002
44. KONINGS CJ, DAMMERS R, RENSMA PL, et al: Arterial wall properties in patients with renal failure. Am J Kidney Dis 39:1206-1212, 2002
45. MURPHY SW, FOLEY RN, BARKETT BJ, et al: Comparative mortality of hemodialysis and peritoneal dialysis in Canada. Kidney Int 57:1720-1726, 2000
46. HIDER RC: Nature of nontransferrin-bound iron. Eur J Clin Invest 32(Suppl 1):50-54, 2002